BRAF and melanoma: We have recently reported about the initial biophysical and biochemical characterization in vitro of LNPs carrying both miR-204-5p and miR-199-5p (LNP-miRs) and showed that they are able to reduce BRAF mutant melanoma cell growth alone and in combination with MAPKi, both in drug sensitive and drug resistant melanoma cells in vitro [26].